LIAN vs. ALRN, UBX, DYAI, SYBX, CLRB, TCON, PIRS, NERV, NRXS, and PHXM
Should you be buying LianBio stock or one of its competitors? The main competitors of LianBio include Aileron Therapeutics (ALRN), Unity Biotechnology (UBX), Dyadic International (DYAI), Synlogic (SYBX), Cellectar Biosciences (CLRB), TRACON Pharmaceuticals (TCON), Pieris Pharmaceuticals (PIRS), Minerva Neurosciences (NERV), NeurAxis (NRXS), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "biotechnology" industry.
Aileron Therapeutics (NASDAQ:ALRN) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, community ranking, profitability, analyst recommendations, valuation and dividends.
Aileron Therapeutics' return on equity of -33.17% beat LianBio's return on equity.
Aileron Therapeutics received 207 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 66.77% of users gave Aileron Therapeutics an outperform vote while only 36.36% of users gave LianBio an outperform vote.
Aileron Therapeutics currently has a consensus target price of $9.00, suggesting a potential upside of 26.94%. LianBio has a consensus target price of $5.33, suggesting a potential upside of 1,642.07%. Given Aileron Therapeutics' higher probable upside, analysts plainly believe LianBio is more favorable than Aileron Therapeutics.
In the previous week, Aileron Therapeutics and Aileron Therapeutics both had 3 articles in the media. Aileron Therapeutics' average media sentiment score of 1.08 beat LianBio's score of 0.96 indicating that LianBio is being referred to more favorably in the news media.
90.9% of Aileron Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 5.6% of Aileron Therapeutics shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Aileron Therapeutics has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.
Summary
Aileron Therapeutics beats LianBio on 6 of the 11 factors compared between the two stocks.
Get LianBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools